TERPS Trial for de Novo Oligometastic Prostate Cancer
NCT05223803
This study is recruiting at 10 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Oligometastatic Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- University of Maryland, Baltimore
- Last updated on ClinicalTrials.gov
- June 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UC San Diego Moores Cancer Center · La Jolla, CA
Kansas · 1
- KU Medical Center- Cancer Center · Kansas City, KS
Maryland · 5
- Maryland Proton Treatment Center · Baltimore, MD
- UMMC · Baltimore, MD
- Upper Chesapeake Health · Bel Air, MD
- Central Maryland Radiation Oncology · Columbia, MD
- Baltimore Washington Medical Center · Glen Burnie, MD
Pennsylvania · 2
- Sidney Kimmel Cancer Center at Jefferson Health · Philadelphia, PA
- UPMC Hillman Cancer Center · Pittsburgh, PA
Virginia · 1
- Bon Secours Cancer Institute at St. Francis · Midlothian, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.